These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 15284295

  • 21. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
    Mamoune A, Kassis J, Kharait S, Kloeker S, Manos E, Jones DA, Wells A.
    Exp Cell Res; 2004 Sep 10; 299(1):91-100. PubMed ID: 15302576
    [Abstract] [Full Text] [Related]

  • 22. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK).
    Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L.
    Cancer Res; 2003 Apr 01; 63(7):1684-95. PubMed ID: 12670923
    [Abstract] [Full Text] [Related]

  • 23. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
    Jardí M, Inglés-Esteve J, Burgal M, Azqueta C, Velasco F, López-Pedrera C, Miles LA, Félez J.
    Thromb Haemost; 1996 Dec 01; 76(6):1009-19. PubMed ID: 8972026
    [Abstract] [Full Text] [Related]

  • 24. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
    Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H.
    J Urol; 2005 Aug 01; 174(2):461-5. PubMed ID: 16006865
    [Abstract] [Full Text] [Related]

  • 25. Differential expression of the urokinase receptor in fibroblasts from normal and fibrotic human lungs.
    Shetty S, Kumar A, Johnson AR, Pueblitz S, Holiday D, Raghu G, Idell S.
    Am J Respir Cell Mol Biol; 1996 Jul 01; 15(1):78-87. PubMed ID: 8679225
    [Abstract] [Full Text] [Related]

  • 26. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
    Wells JM, Strickland S.
    J Cell Physiol; 1997 May 01; 171(2):217-25. PubMed ID: 9130470
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Urokinase/urokinase receptor system: internalization/degradation of urokinase-serpin complexes: mechanism and regulation.
    Conese M, Blasi F.
    Biol Chem Hoppe Seyler; 1995 Mar 01; 376(3):143-55. PubMed ID: 7612191
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Urokinase-type plasminogen activator receptor regulates leukocyte recruitment during experimental pneumococcal meningitis.
    Paul R, Winkler F, Bayerlein I, Popp B, Pfister HW, Koedel U.
    J Infect Dis; 2005 Mar 01; 191(5):776-82. PubMed ID: 15688295
    [Abstract] [Full Text] [Related]

  • 33. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
    Webb DJ, Thomas KS, Gonias SL.
    J Cell Biol; 2001 Feb 19; 152(4):741-52. PubMed ID: 11266465
    [Abstract] [Full Text] [Related]

  • 34. Expression of urokinase-type plasminogen activator and its receptor is up-regulated during tendon healing.
    Xia W, de Bock C, Murrell GA, Wang Y.
    J Orthop Res; 2003 Sep 19; 21(5):819-25. PubMed ID: 12919869
    [Abstract] [Full Text] [Related]

  • 35. Epidermal growth factor stimulates urokinase-type plasminogen activator expression in human gingival fibroblasts. Possible modulation by genistein and curcumin.
    Smith PC, Santibañez JF, Morales JP, Martinez J.
    J Periodontal Res; 2004 Dec 19; 39(6):380-7. PubMed ID: 15491342
    [Abstract] [Full Text] [Related]

  • 36. PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor.
    Degryse B, Sier CF, Resnati M, Conese M, Blasi F.
    FEBS Lett; 2001 Sep 14; 505(2):249-54. PubMed ID: 11566185
    [Abstract] [Full Text] [Related]

  • 37. Effects of hypoxia and reoxygenation on the expression levels of the urokinase-type plasminogen activator, its inhibitor plasminogen activator inhibitor type-1 and the urokinase-type plasminogen activator receptor in human head and neck tumour cells.
    Sprague LD, Tomaso H, Mengele K, Schilling D, Bayer C, Stadler P, Schmitt M, Molls M.
    Oncol Rep; 2007 May 14; 17(5):1259-68. PubMed ID: 17390074
    [Abstract] [Full Text] [Related]

  • 38. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C, Gavin O, Kruithof EK.
    Thromb Haemost; 2000 Feb 14; 83(2):290-6. PubMed ID: 10739388
    [Abstract] [Full Text] [Related]

  • 39. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
    Yebra M, Goretzki L, Pfeifer M, Mueller BM.
    Exp Cell Res; 1999 Jul 10; 250(1):231-40. PubMed ID: 10388537
    [Abstract] [Full Text] [Related]

  • 40. MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.
    Bessard A, Frémin C, Ezan F, Coutant A, Baffet G.
    J Cell Physiol; 2007 Aug 10; 212(2):526-36. PubMed ID: 17427199
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.